Show simple item record

dc.contributor.authorJamieson, D
dc.contributor.authorGriffin, M
dc.contributor.authorSludden, J
dc.contributor.authorDrew, Y
dc.contributor.authorCresti, N
dc.contributor.authorSwales, K
dc.contributor.authorMerriman, M
dc.contributor.authorAllen, R
dc.contributor.authorBevan, P
dc.contributor.authorBuerkle, M
dc.contributor.authorMala, C
dc.contributor.authorCoyle, V
dc.contributor.authorRodgers, L
dc.contributor.authorDean, Emma J
dc.contributor.authorGreystoke, A
dc.contributor.authorBanerji, U
dc.contributor.authorWilson, R
dc.contributor.authorEvans, T
dc.contributor.authorAnthoney, A
dc.contributor.authorRanson, Malcolm R
dc.contributor.authorBoddy, A
dc.contributor.authorPlummer, R
dc.date.accessioned2016-10-21T14:05:51Z
dc.date.available2016-10-21T14:05:51Z
dc.date.issued2016-09-28
dc.identifier.citationA phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. 2016, 68:1-10 Eur. J. Canceren
dc.identifier.issn1879-0852
dc.identifier.pmid27693888
dc.identifier.doi10.1016/j.ejca.2016.08.026
dc.identifier.urihttp://hdl.handle.net/10541/619962
dc.description.abstractWe performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determine the optimal biological dose for subsequent trials.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to European journal of cancer (Oxford, England : 1990)en
dc.titleA phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.en
dc.typeArticleen
dc.contributor.departmentNorthern Institute for Cancer Research, Paul O'Gorman Building, Medical School, Newcastle University, Newcastle upon Tyne, NE2 4HH,en
dc.identifier.journalEuropean Journal of Canceren
refterms.dateFOA2020-04-21T13:13:40Z
html.description.abstractWe performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small molecule mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor, WX-554, and to determine the optimal biological dose for subsequent trials.


Files in this item

Thumbnail
Name:
559021.pdf
Size:
2.328Mb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record